Saturday 17 October 2026
Export COCP’s income statement to Excel — free account
Cocrystal Pharma, Inc.
COCP Healthcare Biotechnology
In the quarter to June 2026, revenue fell 81.1%, EPS fell 15.0% and free cash flow fell 16.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.02
0.01
−0.97%
Follow COCP
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
— | — | — | 2.43 | 37.27 | — | — | — | — | — |
Altman Z-Score |
— | — | — | (13.28) | 19.78 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | (27.34) | 19.78 | — | — | — | — | — |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
P/Operating CF |
— | — | — | (12.95) | (31.53) | — | — | — | — | — |
Beneish M-Score |
— | — | — | — | (1.65) | — | — | — | — | — |
P/B ratio |
— | — | — | 0.62 | 1.43 | — | — | — | — | — |
Price to Tangible BV |
— | — | — | 2.41 | 2.25 | — | — | — | — | — |
EV/Sales |
— | — | — | 1.29 | 20.87 | — | — | — | — | — |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
— | — | — | (5.42) | (4.28) | — | — | — | — | — |
EV/FCF |
— | — | — | (4.96) | (4.17) | — | — | — | — | — |
Quick Ratio |
2.43 | 1.44 | 1.77 | 3.55 | 24.75 | 38.03 | 31.20 | 8.37 | 4.59 | 3.53 |
Current Ratio |
2.68 | 1.51 | 1.89 | 3.62 | 25.05 | 38.40 | 33.04 | 8.92 | 4.77 | 3.68 |
Net Debt/EBITDA |
0.03 | (0.03) | 0.04 | 3.64 | 3.57 | 4.25 | 1.92 | 1.32 | 0.57 | 0.82 |
Debt/Assets |
0.00% | 0.83% | 0.17% | 0.05% | 0.06% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.14 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.20 | 11.26 | 0.17 | 0.03 | 1.02 | 0.90 | 0.55 | 0.82 | 0.94 | 0.93 |
Capex/Depreciation |
(0.25) | (0.40) | (0.56) | 0.00 | (0.71) | (0.14) | 0.00 | 0.09 | (0.02) | (0.03) |
Interest Coverage |
(839.83) | (1,180.29) | (1,084.90) | (2,547.68) | (1,198.25) | (3,555.25) | (19,414.50) | 29.00 | — | — |
| (55.48%) | (0.59%) | (56.94%) | (104.04%) | (24.67%) | (21.81%) | (66.32%) | (54.54%) | (97.50%) | (111.40%) | |
| (42.89%) | (0.50%) | (51.63%) | (99.22%) | (23.31%) | (21.23%) | (64.60%) | (49.89%) | (78.29%) | (76.23%) | |
ROIC |
(67.02%) | (4.89%) | (61.21%) | (165.74%) | (30.76%) | (47.27%) | (1,033.57%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(2,016.54%) | (71.45%) | (2,771.07%) | (749.60%) | (29.02%) | (24.36%) | (98.81%) | (68.90%) | (188.11%) | (146.77%) |
Average Days of Receivables |
0.00 | 0.00 | — | 35.81 | 100.76 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 61.00% | 299.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 74.09% | 276.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.52 | 0.54 | 0.95 | 0.67 | 0.35 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 5.35% | 32.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | 0.34 | 0.43 | — | — | — | — | — |
Graham Number |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
— | — | — | (302.12%) | (13.24%) | — | — | — | — | — |
Free Cash Flow Yield |
— | — | — | (10.73%) | (13.41%) | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 2.47 | 0.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(7.48) | (3.43) | (3.55) | (0.59) | (2.14) | (1.73) | (2.63) | (1.52) | (1.62) | (0.73) |
Capex per Share |
(0.03) | (0.02) | (0.01) | (0.05) | (0.05) | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
(7.51) | (3.45) | (3.57) | (0.64) | (2.19) | (1.73) | (2.64) | (1.53) | (1.62) | (0.73) |
Cash per Share |
1.86 | 0.39 | 1.18 | 2.81 | 7.19 | 7.98 | 4.57 | 2.74 | 0.98 | 0.63 |
Shareholders Equity per Share |
52.23 | 52.45 | 28.67 | 9.69 | 11.42 | 10.53 | 4.86 | 2.73 | 0.94 | 0.56 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
52.23 | 52.45 | 28.67 | 9.69 | 11.42 | 10.53 | 4.86 | 2.73 | 0.94 | 0.56 |
Free Cash Flow |
(14.71) | (6.94) | (8.32) | (1.71) | (10.07) | (12.77) | (21.51) | (14.78) | (16.49) | (8.20) |
Working Capital |
3.43 | 0.74 | 1.39 | 6.00 | 32.66 | 57.78 | 38.96 | 25.83 | 9.15 | 5.92 |
Capital Expenditures |
(0.05) | (0.04) | (0.03) | (0.14) | (0.24) | (0.05) | (0.07) | (0.12) | (0.01) | (0.01) |
Net Current Asset Value |
(17.09) | (13.85) | 1.27 | 5.46 | 32.28 | 57.48 | 38.91 | 24.22 | 7.65 | 4.75 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.72 | 0.85 | 0.13 | 107.56 | 0.57 | 0.84 | 56.96 | (5.12) | 2.92 | 4.04 |
Cash ROIC |
(13.88%) | (6.48%) | (11.92%) | (5.15%) | (11.76%) | (9.37%) | (28.01%) | (27.99%) | (84.76%) | (61.08%) |
Accounts Receivable Turnover |
0.00 | 0.00 | — | 6.77 | 3.36 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.76 | 1.30 | — | 0.97 | 0.60 | — | 0.64 | 0.80 | 1.05 | 0.96 |
Average Payables |
1.57 | 0.70 | 0.96 | 1.54 | 1.54 | 1.19 | 1.14 | 2.00 | 2.57 | 2.00 |
Average Assets |
174.56 | 123.15 | 94.99 | 48.55 | 41.39 | 66.82 | 60.12 | 36.05 | 22.36 | 11.58 |
Average Common Equity |
134.96 | 103.86 | 86.14 | 46.30 | 39.11 | 65.03 | 58.56 | 32.98 | 17.95 | 7.93 |
Columns are period end dates